

# To determine whether reconstruction of pancreatic remnant with the stomach after pancreatoduodenotomy can be safe and acceptably decreases the rate of pancreatic fistulas compared with reconstruction with the small bowel

<b>Submission date</b> 20/01/2013	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 07/02/2013	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
<b>Last Edited</b> 21/10/2016	<b>Condition category</b> Surgery	<input type="checkbox"/> Individual participant data

## Plain English summary of protocol

### Background and study aims

Pancreaticoduodenectomy (PD) is surgery to remove part of the pancreas and part of the stomach. It is the best treatment for patients with pancreatic cancer. However, PD can lead to leakage (called pancreatic fistula) with a significant risk of illness and death. It is not known which reconstruction method is to best at reducing the risk of fistula. Pancreaticojejunostomy (PJ) involves connecting the remnant of the pancreas to the middle portion of the small intestine, and is the most commonly used reconstructive method after PD.

Pancreaticogastrostomy (PG) involves connecting the remnant of the pancreas to the stomach, and may have a lower risk of fistula. The aim of this study is to compare the rate of fistula and other complications between both methods.

### Who can participate?

Patients aged 18 to 80 undergoing PD for pancreatic tumours, chronic pancreatitis (long-term inflammation of the pancreas), or cancer that has spread to the pancreas

### What does the study involve?

Participants are randomly allocated to one of two groups. One group undergoes PG surgery while the other group undergoes PJ surgery. Rate of pancreatic fistula, complications, further surgery, illness and death are measured in both groups at the time of hospital discharge and 3 months later.

What are the possible benefits and risks of participating?

There will be no immediate direct benefit to those taking part, but there may be a lower rate of pancreatic fistula with the PG surgery, which could benefit future patients. Previous studies suggest that PG is at least as safe as PJ.

Where is the study run from?

Hospital Clinico de Valencia and Hospital "Dr Josep Trueta" in Girona (Spain)

When is the study starting and how long is it expected to run for?

February 2008 to February 2013

Who is funding the study?

Instituto de Salud Carlos III (Spain)

Who is the main contact?

Prof. Joan Figueras Felip

info@jfigueras.net

## Contact information

### Type(s)

Scientific

### Contact name

Prof Joan Figueras Felip

### Contact details

Hepato-biliary and pancreatic surgery

Department of Surgery

Dr Josep Trueta Hospital

Girona

Spain

17007

+34 (0)972 940 256

info@jfigueras.net

## Additional identifiers

### Protocol serial number

PI08621

## Study information

### Scientific Title

Pancreatogastrostomy vs. pancreatojejunostomy for reconstruction of the pancreatic remnant after pancreatoduodenotomy: a prospective, randomised, controlled, metacentre study

### Acronym

PGvsPJ

**Study objectives**

Pancreato-gastric anastomosis of the pancreas with the stomach after pancreatoduodenotomy presents less incidence of pancreatic fistula than the standard reconstruction with pancreato-jejunostomy.

**Ethics approval required**

Old ethics approval format

**Ethics approval(s)**

Ethics committee of the Doctor Josep Trueta University Hospital in Girona, 01/02/2008

**Study design**

Randomised prospective controlled parallel-group multicentre trial

**Primary study design**

Interventional

**Study type(s)**

Treatment

**Health condition(s) or problem(s) studied**

Pancreatectomy

**Interventions**

Group PG: Pancreatogastric anastomosis of the pancreatic remnant to the stomach

Group PJ: Pancreatojejunostomy anastomosis of the pancreatic remnant to the jejunum

**Intervention Type**

Procedure/Surgery

**Phase**

Not Applicable

**Primary outcome(s)**

Rate of pancreatic fistula, evaluated at the time of hospital discharge and at 3 months post-operatively. The severity of the PF will be evaluated with the ISGPH score.

**Key secondary outcome(s)**

1. Mortality and morbidity
  2. Complications graded according to Dindo-Clavien classification
  3. Reoperation rate
  4. Readmissions and hospital stay
- Evaluated at the time of hospital discharge and at 3 months post-operatively.

**Completion date**

28/02/2013

**Eligibility****Key inclusion criteria**

1. Consecutive patients who will undergo pancreatodudodenectomy (DPC) at Hospital Clinico de Valencia and Hospital Dr Josep Trueta in Girona Spain. Coordinated by Dr Josep Trueta Hospital of Girona
2. Patients aged 18 to 80 years, either sex
3. Pancreatectomy is indicated because of a benign or malignant tumour of the pancreas, chronic pancreatitis or malignant neoplasm of other organs infiltrating the pancreas, provided the parenchyma of the pancreas is suitable for anastomosis

**Participant type(s)**

Patient

**Healthy volunteers allowed**

No

**Age group**

Adult

**Lower age limit**

18 years

**Sex**

All

**Key exclusion criteria**

1. Patients who at the time of surgery are found not resectable
2. Associated resection of other organs, excluding the superior mesenteric vein
3. American Society of Anaesthesiologists (ASA) anesthetic risk 4 as the American Association of Anesthesiologists
4. Pancreatoduodenectomy (PD) for calcifying chronic pancreatitis
5. PD palliative leaving macroscopic tumor
6. Preoperative obstructive jaundice with bilirubin > 300µmol or 15 mg/L

**Date of first enrolment**

22/02/2008

**Date of final enrolment**

28/02/2013

**Locations****Countries of recruitment**

Spain

**Study participating centre**

Dr Josep Trueta Hospital

Girona

Spain

17007

# Sponsor information

## Organisation

Carlos III Institute of Health (Instituto de Salud Carlos III) (Spain)

## ROR

<https://ror.org/00ca2c886>

# Funder(s)

## Funder type

Hospital/treatment centre

## Funder Name

Instituto de Salud Carlos III (Spain) FIS (Registration number PI08621)

# Results and Publications

## Individual participant data (IPD) sharing plan

## IPD sharing plan summary

Not provided at time of registration

## Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>	results	01/11/2013		Yes	No
<a href="#">Participant information sheet</a>	Participant information sheet	11/11/2025	11/11/2025	No	Yes